欢迎来到CSNpharm！产品仅用于科研！

400-920-2911 sales@csnpharm.cn

NEW 新产品
0

Bcl-2

Bcl-2

货号 产品名 CAS号 信息
CSN17851 WEHI-539 1431866-33-9 WEHI-539 is a selective inhibitor of Bcl-XL with IC50 of 1.1 nM.
CSN18898 WEHI-539 hydrochloride 2070018-33-4 WEHI-539 HCl is a selective inhibitor of Bcl-XL with IC50 of 1.1 nM.
CSN18313 UMI-77 518303-20-3 UMI-77 is a selective Mcl-1 SMI inhibitor, binding to the BH3 binding groove of Mcl-1 with Ki of 490 nM.
CSN16145 TW-37 877877-35-5 TW-37 is a nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM, respectively.
CSN23122 Smba 1 906440-37-7 SMBA1 is a selective activator of Bax, a central death regulator. It acts by potently suppressing lung tumour growth via apoptosis.
CSN19228 Sabutoclax 1228108-65-3 Sabutoclax is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
CSN19712 S63845 1799633-27-4 S63845 specifically binds with high affinity to the BH3-binding groove of MCL1. S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway.
CSN22926 S55746 1448584-12-0 S55746 is a potent and selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities.
CSN32507 S65487 1644600-79-2 S-65487 is a Bcl-2 inhibitor.
CSN18897 Pyridoclax 1651890-44-6 Pyridoclax is a potent Mcl-1 inhibitor with Kd value of 25 nM.
CSN23774 ML311 315698-17-0 ML311, also known as EU-5346, is a selective inhibitor of the interaction of Mcl-1 and Bim.
CSN18308 MIM1 509102-00-5 MIM1 is a selective small molecule inhibitor of Mcl-1(IC50= 4.8 uM) that overcomes Mcl-1-dependent leukemia cell survival.
CSN21100 MIK665 1799631-75-6 MIK665 is an inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities.
CSN22462 Mcl1-IN-4 1580484-04-3 Mcl1-IN-4 is an inhibitor of Mcl1 with an IC50 of 0.2 μM.
CSN18186 IMB-XH1 292057-76-2 Mcl1-IN-2 is a Mcl-1 inhibitor without reported IC50 value.
CSN18401 Mcl1-IN-1 713492-66-1 Mcl1-IN-1 is a potent Mcl-1-selective inhibitor relative to the related Bcl-2 family protein Bcl-xL and demonstrates good Mcl-1 inhibition (IC50 = 2.4 uM) with no appreciable inhibition of Bcl-xL at 100 uM.
CSN17591 Maritoclax 1227962-62-0 Marinopyrrole A is a selective Mcl-1 inhibitor with IC50 of 10.1 μM and proapoptosis properties in some cancer cells.
CSN33176 Lisaftoclax 2180923-05-9 Lisaftoclax is a Bcl-2 Inhibitor.
CSN14611 Isochamaejasmine 93859-63-3 Isochamaejasmine, a natural product isolated and purified from the roots of Stellera chamaejasme Linn., has inhibition of NF-kappaB activation reversed the anti-apoptotic effect, shows antiplasmodial activity, with an IC(50) of 7.3+/-3.8 mM, but the selectivity was rather limited, and induces apoptosis in leukemia cells by inhibiting the activity of Bcl-2 family proteins, providing evidence for further studying the underlying anti-cancer mechanism of S.
CSN26420 Gossypol (acetic acid) 12542-36-8 Gossypol acetic, a natural product isolated from cottonseeds and roots, binds to Bcl-xL protein and Bcl-2 protein with Kis of 0.5-0.6 μM and 0.2-0.3 mM, respectively.
CSN13795 Gambogic Acid 2752-65-0 Gambogic acid activates caspases with EC50 of 0.78-1.64 μM and competitively inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50 of 1.47, 1.21, 2.02, 0.66, 1.06 and 0.79 μM, respectively.
CSN22317 FX1 1426138-42-2 FX1 is a BCL6 inhibitor that effectively blocks BCL6 N-terminal BTB domain-mediated corepressors chromosome recruitment (by 61-87%/SMRT and 67-82%/BCOR; 50 μM FX1 for 30 min) and selectively suppresses BCL6-depenent growth (GI50 16-54 μM; >125 μM against BCL6-independent cells) in diffuse large B cell lymphoma (DLBCL) cultures, exhibiting greater affinity than its structure analog 79-6 or BCL6 corepressor SMRT for BTB domain (KD = 7 μM/FX1, 30 μM/SMRT, 129 μM/79-6). FX1 shows greater efficacy than 79-6 in reversing BCL6/corepressors-mediated target genes repression in vitro (IC50 = 35 μM vs. 318 μM with 79-6 by HEK293T-based reporter assay) and in suppressing OCI-Ly7 DLBCL xenograft tumor growth mice in vivo (100% vs. 45% suppression with respective compound via 25 mg/kg/day i.p.).
CSN26636 (2S,4R)-1-((S)-2-(7-(4-((R)-3-((4-(N-(4-(4-((4'-Chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoyl)sulfamoyl)-2-((trifluoromethyl)sulfonyl)phenyl)amino)-4-(phenylthio)butyl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide 2365172-42-3 DT2216 is a selective B-cell lymphoma extra large (BCL-XL) proteolysis-targeting chimera (PROTAC). DT2216 targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for degradation. DT2216 inhibits various BCL-XL-dependent leukemia and cancer cells but considerably less toxic to platelets
CSN20561 CID5721353 301356-95-6 CID5721353 is a B-Cell Lymphoma 6 inhibitor (BCL6 inhibitor).
CSN23343 BTSA1 314761-14-3 BTSA1 is a BAX activator that binds to the N-terminal activation site with high affinity and specificity, induces conformational changes to BAX leading to BAX-mediated apoptosis.
CSN27381 BT2 34576-94-8 BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC). BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM.
CSN24699 BI-6C9 791835-21-7 BI-6C9 is a Bid inhibitor, which prevents mitochondrial outer membrane potential (MOMP) and mitochondrial fission, and protects the cells from cell death.
CSN22193 BI-3812 2166387-64-8 BI-3812 is a BCL6 inhibitor, inhibiting the BTB domain of BCL6, with an IC50 of ≤3 nM.
CSN22358 BI-3802 2166387-65-9 BI-3802 is a highly potent BCL6 degrader, inhibiting the BTB domain of BCL6, with an IC50 of ≤3 nM; BI-3802 has antitumor activity.
CSN18193 BH3I-1 300817-68-9 BH3I-1 is an inhibitor of Bcl-xL with IC50 of 293.95 μM.
CSN27660 BCL6-IN-7 2097518-46-0 BCL6-IN-7 is a potent BCL6 protein-protein interaction inhibitor with Kd of 78 nM.
CSN27291 BCL6-IN-5   2253878-09-8 BCL6-IN-5 is a potent BCL6 inhibitor exacted from patent WO2018215801A1 with pIC50 of 5.82.
CSN18341 Bax inhibitor peptide V5 579492-81-2 Bax inhibitor peptide V5 is a Bax-mediated apoptosis inhibitor, used for cancer treatment.
CSN16589 BAM7 331244-89-4 BAM 7 is a direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
CSN23881 BAI1 335165-68-9 BAI1 is an inhibitor of Bax-mediated mitochondrial cytochrome c release (IC50 = 0.52 μM).
CSN21099 AZD-5991 2143061-81-6 AZD5991 is a potent and selective Mcl-1 inhibitor for treatment of hematologic cancers （a phase I trial of Haematological malignancies）.
CSN21081 AZD4320 1357576-48-7 AZD4320 is a dual inhibitor of BCL-2 and BCL-xl.
CSN18551 (R)-(-)-Gossypol 90141-22-3 AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM.
CSN18501 (R)-(-)-Gossypol acetic acid 866541-93-7 AT101 acetic acid, the R-(-) enantiomer of gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM.
CSN20524 Tapotoclax 1883727-34-1 AMG-176 is an inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities.
CSN17604 A-1155463 1235034-55-5 A1155463 is a highly potent and selective BCL-XL inhibitor with an EC50 value of 70 nM in Molt-4 cell.
CSN16885 A-1210477 1668553-26-1 A-1210477 is a potent and selective inhibitor of MCL-1, and weakly binds to BCL-2 and BCL-XL, with Ki of 0.45 nM, 132 nM and > 660 nM, respectively.
CSN17536 (S)-Gossypol (acetic acid) 1189561-66-7 (S)-Gossypol acetic acid is an inhibitor of Bcl-2, potently induce cell death in Jurkat cells overexpressing Bcl-2 (IC50, 18.1μM) or Bcl-xL (IC50, 22.9μM).
CSN18376 (+)-Apogossypol 66389-74-0 (+)-Apogossypol is a potent inhibitor of Bcl-2 family proteins and competes with the BH3 peptide-binding sites on Bcl-2, Bcl-XL, Mcl-1, Bcl-W, and Bcl-B, but not Bfl-1, with IC50s of 0.5 to 2 μM.
<< PREV 1 2 NEXT >>
dandb BBB norton fedex dhl ups 顺丰

csnpharm版权所有2023，产品仅用于科研！

联系
我们